6xi2
From Proteopedia
(Difference between revisions)
(New page: '''Unreleased structure''' The entry 6xi2 is ON HOLD Authors: Halmo, S.M., Yeh, J., Wells, L., Moremen, K.W., Lanzilotta, W.N. Description: Apo form of POMGNT2 [[Category: Unreleased S...) |
|||
(3 intermediate revisions not shown.) | |||
Line 1: | Line 1: | ||
- | '''Unreleased structure''' | ||
- | The entry | + | ==Apo form of POMGNT2== |
+ | <StructureSection load='6xi2' size='340' side='right'caption='[[6xi2]], [[Resolution|resolution]] 2.57Å' scene=''> | ||
+ | == Structural highlights == | ||
+ | <table><tr><td colspan='2'>[[6xi2]] is a 6 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6XI2 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6XI2 FirstGlance]. <br> | ||
+ | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.57Å</td></tr> | ||
+ | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr> | ||
+ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6xi2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6xi2 OCA], [https://pdbe.org/6xi2 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6xi2 RCSB], [https://www.ebi.ac.uk/pdbsum/6xi2 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6xi2 ProSAT]</span></td></tr> | ||
+ | </table> | ||
+ | == Disease == | ||
+ | [https://www.uniprot.org/uniprot/PMGT2_HUMAN PMGT2_HUMAN] Walker-Warburg syndrome. The disease is caused by variants affecting the gene represented in this entry. The disease is caused by variants affecting the gene represented in this entry. | ||
+ | == Function == | ||
+ | [https://www.uniprot.org/uniprot/PMGT2_HUMAN PMGT2_HUMAN] O-linked mannose beta-1,4-N-acetylglucosaminyltransferase that transfers UDP-N-acetyl-D-glucosamine to the 4-position of the mannose to generate N-acetyl-D-glucosamine-beta-1,4-O-D-mannosylprotein. Involved in the biosynthesis of the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3-N-acetylglucosamine-beta-4-(phosphate-6-)mannose), a carbohydrate structure present in alpha-dystroglycan (DAG1), which is required for binding laminin G-like domain-containing extracellular proteins with high affinity.<ref>PMID:23929950</ref> <ref>PMID:27066570</ref> | ||
+ | <div style="background-color:#fffaf0;"> | ||
+ | == Publication Abstract from PubMed == | ||
+ | The canonical O-mannosylation pathway in humans is essential for the functional glycosylation of alpha-dystroglycan. Disruption of this post-translational modification pathway leads to congenital muscular dystrophies. The first committed step in the construction of a functional matriglycan structure involves the post-translational modification of alpha-dystroglycan. This is essential for binding extracellular matrix proteins and arenaviruses, and is catalyzed by beta-1,4-N-acetylglucosaminyltransferase 2 (POMGNT2). While another glycosyl transferase, beta-1,4-N-acetylglucosaminyltransferase 1 (POMGNT1), has been shown to be promiscuous in extending O-mannosylated sites, POMGNT2 has been shown to display significant primary amino-acid selectivity near the site of O-mannosylation. Moreover, several single point mutations in POMGNT2 have been identified in patients with assorted dystroglycanopathies such as Walker-Warburg syndrome and limb girdle muscular dystrophy. To gain insight into POMGNT2 function in humans, the enzyme was expressed as a soluble, secreted fusion protein by transient infection of HEK293 suspension cultures. Here, crystal structures of POMGNT2 (amino-acid residues 25-580) with and without UDP bound are reported. Consistent with a novel fold and a unique domain organization, no molecular-replacement model was available and phases were obtained through crystallization of a selenomethionine variant of the enzyme in the same space group. Tetragonal (space group P4212; unit-cell parameters a = b = 129.8, c = 81.6 A, alpha = gamma = beta = 90 degrees ) crystals with UDP bound diffracted to 1.98 A resolution and contained a single monomer in the asymmetric unit. Orthorhombic (space group P212121; unit-cell parameters a = 142.3, b = 153.9, c = 187.4 A, alpha = gamma = beta = 90 degrees ) crystals were also obtained; they diffracted to 2.57 A resolution and contained four monomers with differential glycosylation patterns and conformations. These structures provide the first rational basis for an explanation of the loss-of-function mutations and offer significant insights into the mechanics of this important human enzyme. | ||
- | + | Crystal structures of beta-1,4-N-acetylglucosaminyltransferase 2: structural basis for inherited muscular dystrophies.,Yang JY, Halmo SM, Praissman J, Chapla D, Singh D, Wells L, Moremen KW, Lanzilotta WN Acta Crystallogr D Struct Biol. 2021 Apr 1;77(Pt 4):486-495. doi:, 10.1107/S2059798321001261. Epub 2021 Mar 30. PMID:33825709<ref>PMID:33825709</ref> | |
- | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
- | [[Category: | + | </div> |
- | [[Category: | + | <div class="pdbe-citations 6xi2" style="background-color:#fffaf0;"></div> |
- | [[Category: Lanzilotta | + | == References == |
- | [[Category: | + | <references/> |
- | [[Category: | + | __TOC__ |
- | [[Category: | + | </StructureSection> |
+ | [[Category: Homo sapiens]] | ||
+ | [[Category: Large Structures]] | ||
+ | [[Category: Halmo SM]] | ||
+ | [[Category: Lanzilotta WN]] | ||
+ | [[Category: Moremen KW]] | ||
+ | [[Category: Wells L]] | ||
+ | [[Category: Yeh J]] |
Current revision
Apo form of POMGNT2
|